Logo image of ADN1.DE

ADESSO SE (ADN1.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:ADN1 - DE000A0Z23Q5 - Common Stock

88.9 EUR
+0.2 (+0.23%)
Last: 1/2/2026, 11:38:20 AM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ADN1. ADN1 was compared to 68 industry peers in the IT Services industry. ADN1 has an average financial health and profitability rating. ADN1 is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

ADN1 had positive earnings in the past year.
ADN1 had a positive operating cash flow in the past year.
ADN1 had positive earnings in each of the past 5 years.
ADN1 had a positive operating cash flow in each of the past 5 years.
ADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of 2.45%, ADN1 is doing worse than 63.24% of the companies in the same industry.
ADN1's Return On Equity of 10.90% is in line compared to the rest of the industry. ADN1 outperforms 47.06% of its industry peers.
ADN1's Return On Invested Capital of 5.23% is on the low side compared to the rest of the industry. ADN1 is outperformed by 66.18% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ADN1 is significantly below the industry average of 11.04%.
The 3 year average ROIC (3.16%) for ADN1 is below the current ROIC(5.23%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROIC 5.23%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ADN1.DE Yearly ROA, ROE, ROICADN1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

Looking at the Profit Margin, with a value of 0.99%, ADN1 is doing worse than 67.65% of the companies in the same industry.
In the last couple of years the Profit Margin of ADN1 has declined.
ADN1's Operating Margin of 2.96% is on the low side compared to the rest of the industry. ADN1 is outperformed by 69.12% of its industry peers.
ADN1's Operating Margin has declined in the last couple of years.
The Gross Margin of ADN1 (85.30%) is better than 75.00% of its industry peers.
ADN1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
ADN1.DE Yearly Profit, Operating, Gross MarginsADN1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ADN1 is destroying value.
The number of shares outstanding for ADN1 has been reduced compared to 1 year ago.
The number of shares outstanding for ADN1 has been increased compared to 5 years ago.
ADN1 has a better debt/assets ratio than last year.
ADN1.DE Yearly Shares OutstandingADN1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADN1.DE Yearly Total Debt VS Total AssetsADN1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ADN1 has an Altman-Z score of 3.62. This indicates that ADN1 is financially healthy and has little risk of bankruptcy at the moment.
ADN1 has a Altman-Z score of 3.62. This is in the better half of the industry: ADN1 outperforms 75.00% of its industry peers.
ADN1 has a debt to FCF ratio of 7.88. This is a slightly negative value and a sign of low solvency as ADN1 would need 7.88 years to pay back of all of its debts.
With a Debt to FCF ratio value of 7.88, ADN1 is not doing good in the industry: 67.65% of the companies in the same industry are doing better.
ADN1 has a Debt/Equity ratio of 1.60. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of ADN1 (1.60) is worse than 76.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Altman-Z 3.62
ROIC/WACC0.94
WACC5.56%
ADN1.DE Yearly LT Debt VS Equity VS FCFADN1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

ADN1 has a Current Ratio of 1.30. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
ADN1 has a Current ratio (1.30) which is comparable to the rest of the industry.
ADN1 has a Quick Ratio of 1.30. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
ADN1 has a Quick ratio of 1.30. This is in the better half of the industry: ADN1 outperforms 64.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
ADN1.DE Yearly Current Assets VS Current LiabilitesADN1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 200.98% over the past year.
ADN1 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.02% yearly.
The Revenue has grown by 12.60% in the past year. This is quite good.
Measured over the past years, ADN1 shows a very strong growth in Revenue. The Revenue has been growing by 23.60% on average per year.
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%

3.2 Future

ADN1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.75% yearly.
Based on estimates for the next years, ADN1 will show a quite strong growth in Revenue. The Revenue will grow by 10.61% on average per year.
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.75%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.61%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADN1.DE Yearly Revenue VS EstimatesADN1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
ADN1.DE Yearly EPS VS EstimatesADN1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 27.87, which means the current valuation is very expensive for ADN1.
ADN1's Price/Earnings is on the same level as the industry average.
ADN1 is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
ADN1 is valuated correctly with a Price/Forward Earnings ratio of 15.72.
ADN1's Price/Forward Earnings ratio is in line with the industry average.
ADN1 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 27.87
Fwd PE 15.72
ADN1.DE Price Earnings VS Forward Price EarningsADN1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADN1 indicates a somewhat cheap valuation: ADN1 is cheaper than 67.65% of the companies listed in the same industry.
60.29% of the companies in the same industry are more expensive than ADN1, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.42
EV/EBITDA 6.61
ADN1.DE Per share dataADN1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ADN1's earnings are expected to grow with 63.28% in the coming years.
PEG (NY)0.33
PEG (5Y)N/A
EPS Next 2Y76.08%
EPS Next 3Y63.28%

4

5. Dividend

5.1 Amount

ADN1 has a yearly dividend return of 0.85%, which is pretty low.
ADN1's Dividend Yield is comparable with the industry average which is at 2.41.
With a Dividend Yield of 0.85, ADN1 pays less dividend than the S&P500 average, which is at 2.00.
Industry RankSector Rank
Dividend Yield 0.85%

5.2 History

On average, the dividend of ADN1 grows each year by 15.65%, which is quite nice.
Dividend Growth(5Y)15.65%
Div Incr Years5
Div Non Decr Years6
ADN1.DE Yearly Dividends per shareADN1.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

ADN1 pays out 31.75% of its income as dividend. This is a sustainable payout ratio.
ADN1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP31.75%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
ADN1.DE Yearly Income VS Free CF VS DividendADN1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADN1.DE Dividend Payout.ADN1.DE Dividend Payout, showing the Payout Ratio.ADN1.DE Dividend Payout.PayoutRetained Earnings

ADESSO SE

FRA:ADN1 (1/2/2026, 11:38:20 AM)

88.9

+0.2 (+0.23%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)11-12 2025-11-12
Earnings (Next)03-31 2026-03-31/amc
Inst Owners20.45%
Inst Owner ChangeN/A
Ins Owners50.28%
Ins Owner ChangeN/A
Market Cap580.52M
Revenue(TTM)2.10B
Net Income(TTM)20.84M
Analysts81.54
Price Target126.63 (42.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.85%
Yearly Dividend0.94
Dividend Growth(5Y)15.65%
DP31.75%
Div Incr Years5
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.91%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-10.47%
EPS NY rev (3m)-10.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.07%
Valuation
Industry RankSector Rank
PE 27.87
Fwd PE 15.72
P/S 0.28
P/FCF 12.42
P/OCF 7.47
P/B 3.04
P/tB 11.46
EV/EBITDA 6.61
EPS(TTM)3.19
EY3.59%
EPS(NY)5.65
Fwd EY6.36%
FCF(TTM)7.16
FCFY8.05%
OCF(TTM)11.9
OCFY13.38%
SpS322.11
BVpS29.27
TBVpS7.75
PEG (NY)0.33
PEG (5Y)N/A
Graham Number45.84
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROCE 11.91%
ROIC 5.23%
ROICexc 5.78%
ROICexgc 8.22%
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
FCFM 2.22%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ROICexc(3y)4.06%
ROICexc(5y)6.01%
ROICexgc(3y)6.65%
ROICexgc(5y)10.11%
ROCE(3y)7.2%
ROCE(5y)10.26%
ROICexgc growth 3Y-20.34%
ROICexgc growth 5Y-12.01%
ROICexc growth 3Y-21.84%
ROICexc growth 5Y-11.01%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
F-Score7
Asset Turnover2.47
Health
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Debt/EBITDA 2.26
Cap/Depr 42.37%
Cap/Sales 1.47%
Interest Coverage 5.03
Cash Conversion 57.42%
Profit Quality 224.33%
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z 3.62
F-Score7
WACC5.56%
ROIC/WACC0.94
Cap/Depr(3y)52.06%
Cap/Depr(5y)49.68%
Cap/Sales(3y)2.64%
Cap/Sales(5y)2.54%
Profit Quality(3y)790.41%
Profit Quality(5y)538.39%
High Growth Momentum
Growth
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.75%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.61%
EBIT growth 1Y38.36%
EBIT growth 3Y-13.12%
EBIT growth 5Y5.01%
EBIT Next Year304.77%
EBIT Next 3Y78.82%
EBIT Next 5Y44.55%
FCF growth 1Y300.77%
FCF growth 3Y40.19%
FCF growth 5Y49.54%
OCF growth 1Y1010.67%
OCF growth 3Y32.14%
OCF growth 5Y37.69%

ADESSO SE / ADN1.DE FAQ

What is the ChartMill fundamental rating of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ADN1.DE.


Can you provide the valuation status for ADESSO SE?

ChartMill assigns a valuation rating of 5 / 10 to ADESSO SE (ADN1.DE). This can be considered as Fairly Valued.


What is the profitability of ADN1 stock?

ADESSO SE (ADN1.DE) has a profitability rating of 4 / 10.


What are the PE and PB ratios of ADESSO SE (ADN1.DE) stock?

The Price/Earnings (PE) ratio for ADESSO SE (ADN1.DE) is 27.87 and the Price/Book (PB) ratio is 3.04.


Can you provide the expected EPS growth for ADN1 stock?

The Earnings per Share (EPS) of ADESSO SE (ADN1.DE) is expected to grow by 83.56% in the next year.